Rent the Runway Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Rent the Runway Inc trades at $1.71 (market cap $61.07M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 79.9× Rent the Runway Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RENT | TVTX | |
|---|---|---|
Market Cap | $61.07M | $4.88B |
Volume | 80,595 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $67.52 |
52-Week Low | $1.55 | $26.79 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $228.07M | $5.01B |
Signals from Pluang's Aura AI — not financial advice
Rent the Runway (RENT) trades at $1.71, down 6.56% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with a gross margin of 74.73%, though net income was -$69.90M. Recent news includes a CEO appointment and multiple law firm investigations into investor claims.
The outlook remains challenging with negative equity and high debt, but improving margins and projected 2026 profitability offer potential. Risks include legal scrutiny and financial leverage, while analyst consensus is cautiously optimistic with 42% buy ratings. Stock performance hinges on execution of turnaround efforts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →